Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: distribute (102), allot (2)

Capecitabine-Streptozocin

Description: Chemotherapy Protocol NEUROENDOCRINE CAPECITABINE-STREPTOZOCIN Regimen • Neuroendocrine – Capecitabine-Streptozocin Indication • Metastatic or locally advance neuroendocrine tumours irrespective of primary site, predominantly
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Capecitabine-Streptozocin.pdf

Anastrozole-Ribociclib

Description: Chemotherapy Protocol Breast Cancer Anastrozole-Ribociclib Regimen • Breast Cancer – Anastrozole-Ribociclib Indication • Ribociclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Anastrozole-Ribociclib.pdf

Abemaciclib-Anastrozole

Description: Chemotherapy Protocol Breast Cancer Abemaciclib-Anastrozole Regimen • Breast Cancer – Abemaciclib-Anastrozole Indication • Abemaciclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Abemaciclib-Anastrozole.pdf

Procedure for making triclyceride emulsion

Description: NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance system for the writing
Url: /Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-making-triclyceride-emulsion.pdf

Erdafitinib

Description: Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or metastatic urothelial cancer harbouring a susceptible fibroblast
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indication • Treatment of adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer – Cyclopho
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

Capecitabine-Cisplatin-Trastuzumab

Description: Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CAPECITABINE-CISPLATIN-TRASTUZUMAB Regimen • Gastrointestinal (Upper) Cancer – Capecitabine-Cisplatin-Trastuzumab Indication • Trastuzumab, in combination with capecitabine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Capecitabine-Cisplatin-Trastuzumab.pdf

Cataract in children - patient information

Description: We have given you this factsheet because your child has been diagnosed with a cataract.
Url: /Media/UHS-website-2019/Patientinformation/Eyes/Childrens-eyes/Cataract-in-children-1782-PIL.pdf

Capecitabine-Carboplatin(AUC5)-Cetuximab

Description: Chemotherapy Protocol HEAD AND NECK CANCER CAPECITABINE-CARBOPLATIN (AUC5)-CETUXIMAB Regimen • Head and Neck Cancer – Capecitabine-Carboplatin-Cetuximab Indication • The treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Capecitabine-Carboplatin-Cetuximab.pdf

151 to 160 of 181

Previous … 14 15 16 17 18 … Next